Recombinant Human VEGF 165, ACFP Protein

Name: Recombinant Human VEGF 165, ACFP Protein
Brand: R&D Systems
SKU: ACFP293

R&D Systems | Catalog # ACFP293

Submit a review

Product Documents

Discontinued Product

ACFP293 has been discontinued. An alternative/replacement product is available: BT-VEGF-AFL. View all VEGF products.

Product Specifications
Preparation & Storage
Calculators
Background
Product Documents
Manufacturing Specifications
Specific Notices
Research Areas
Related Blogs

Key Product Details

Source

Sf 9 (baculovirus)

Accession Number

NP_001165097

Structure / Form

Disulfide-linked homodimer

Applications

Bioactivity

View all VEGF Proteins and Enzymes »

Product Specifications

Source

Spodoptera frugiperda, Sf 9 (baculovirus)-derived human VEGF protein
Met1-Arg191
Produced in an animal component free process (ACFP).

Purity

>97%, by SDS-PAGE under reducing conditions and visualized by silver stain.

Endotoxin Level

<0.01 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Ala27

Predicted Molecular Mass

19.2 kDa (monomer)

SDS-PAGE

19-21 kDa, reducing conditions

Activity

Measured in a cell proliferation assay using HUVEC human umbilical vein endothelial cells. Conn, G. et al. (1990) Proc. Natl. Acad. Sci. USA 87:1323.
The ED₅₀ for this effect is 1-6 ng/mL.
The specific activity of recombinant human VEGF is approximately 1.7 x 10³ U/μg, which is calibrated against recombinant human VEGF 165 WHO Standard (NIBSC code: 02/286).

Formulation, Preparation, and Storage

ACFP293

Formulation	Lyophilized from a 0.2 μm filtered solution in HCl.
Reconstitution	Reconstitute at 100 μg/mL in sterile PBS. Alternatively, reconstitute at 100-500 μg/mL in sterile 4 mM HCl.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Calculators

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Background: VEGF

Vascular endothelial growth factor (VEGF or VEGF‑A), also known as vascular permeability factor (VPF), is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult (1 ‑ 3). It is a member of the PDGF family that is characterized by the presence of eight conserved cysteine residues and a cystine knot structure (4). Humans express alternately spliced isoforms of 121, 145, 165, 183, 189, and 206 amino acids (aa) in length (4). VEGF165 appears to be the most abundant and potent isoform, followed by VEGF121 and VEGF189 (3, 4). Isoforms other than VEGF121 contain basic heparin-binding regions and are not freely diffusible (4). Human VEGF165 shares 88% aa sequence identity with corresponding regions of mouse and rat, 96% with porcine, 95% with canine, and 93% with feline, equine and bovine VEGF, respectively. VEGF binds the type I transmembrane receptor tyrosine kinases VEGF R1 (also called Flt‑1) and VEGF R2 (Flk-1/KDR) on endothelial cells (4). Although VEGF affinity is highest for binding to VEGF R1, VEGF R2 appears to be the primary mediator of VEGF angiogenic activity (3, 4). VEGF165 binds the semaphorin receptor, Neuropilin‑1 and promotes complex formation with VEGF R2 (5). VEGF is required during embryogenesis to regulate the proliferation, migration, and survival of endothelial cells (3, 4). In adults, VEGF functions mainly in wound healing and the female reproductive cycle (3). Pathologically, it is involved in tumor angiogenesis and vascular leakage (6, 7). Circulating VEGF levels correlate with disease activity in autoimmune diseases such as rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosus (8). VEGF is induced by hypoxia and cytokines such as IL-1, IL-6, IL-8, oncostatin M and TNF-alpha (3, 4, 9).

References

Leung, D.W. et al. (1989) Science 246:1306.
Keck, P.J. et al. (1989) Science 246:1309.
Byrne, A.M. et al. (2005) J. Cell. Mol. Med. 9:777.
Robinson, C.J. and Stringer, S.E. (2001) J. Cell. Sci. 114:853.
Pan, Q. et al. (2007) J. Biol. Chem. 282:24049.
Weis, S.M. and D.A. Cheresh (2005) Nature 437:497.
Thurston, G. (2002) J. Anat. 200:575.
Carvalho, J.F. et al. (2007) J. Clin. Immunol. 27:246.
Angelo, L.S. and R. Kurzrock (2007) Clin. Cancer Res. 13:2825.

Long Name

Vascular Endothelial Growth Factor

Alternate Names

MVCD1, VAS, Vasculotropin, VEGF-A, VEGFA, VPF

Entrez Gene IDs

7422 (Human); 22339 (Mouse); 83785 (Rat); 281572 (Bovine); 403802 (Canine); 493845 (Feline); 30682 (Zebrafish)

Gene Symbol

VEGFA

UniProt

NP_001165097

Additional VEGF Products

Product Documents for Recombinant Human VEGF 165, ACFP Protein

Download Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot or batch number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Manufacturing Specifications

Animal Component-Free Process (ACFP) Manufacturing Conditions
R&D Systems Animal Component-Free Process (ACFP) recombinant proteins are expressed in an animal-free certified Sf 9 insect cell line using dedicated animal-free raw materials and labware. Production and purification procedures use equipment and media that are confirmed animal-free but performed outside our dedicated animal-free laboratories. Every stage of the manufacturing process follows R&D Systems' stringent Standard Operating Procedures (SOPs). The certified Sf 9 insect cell bank has undergone extensive testing to certify the lack of cytopathogens by screening for various viruses, Mycoplasma, and Spiroplasmas using both in vitro and in vivo testing methods. For ex vivo research or bioproduction, additional documentation can be provided.

Please read our complete ACFP Statement